ACT-451840

has antimalarial activity; structure in first source

Also Known As:

N-(4-(4-acetylpiperazin-1-yl)benzyl)-3-(4-(tert-butyl)phenyl)-N-(1-(4-(4-cyanobenzyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)acrylamide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Boss, Christoph: 2 articles (11/2021 - 10/2016)
2.	Wittlin, Sergio: 2 articles (11/2021 - 10/2016)
3.	Angulo-Barturen, Iñigo: 1 article (10/2016)
4.	Binkert, Christoph: 1 article (10/2016)
5.	Brun, Reto: 1 article (10/2016)
6.	Brunner, Ralf: 1 article (10/2016)
7.	Buchmann, Stephan: 1 article (10/2016)
8.	Burrows, Jeremy: 1 article (10/2016)
9.	Clozel, Martine: 1 article (10/2016)
10.	Dechering, Koen J: 1 article (10/2016)

1.	Malaria 10/01/2016 - "The determination of the dose-efficacy relationship of ACT-451840 under curative conditions in rodent malaria models allowed prediction of the human efficacious exposure. " 10/01/2016 - "The properties of ACT-451840 are described, including its spectrum of activities against multiple life cycle stages of the human malaria parasite Plasmodium falciparum (asexual and sexual) and Plasmodium vivax (asexual) as well as oral in vivo efficacies in two murine malaria models that permit infection with the human and the rodent parasites P. " 11/24/2021 - "ACT-451840 was clinically investigated up to an experimental human malaria infection model, where therapeutic effects could be shown."
2.	Infections 10/01/2016 - "The properties of ACT-451840 are described, including its spectrum of activities against multiple life cycle stages of the human malaria parasite Plasmodium falciparum (asexual and sexual) and Plasmodium vivax (asexual) as well as oral in vivo efficacies in two murine malaria models that permit infection with the human and the rodent parasites P. " 11/24/2021 - "ACT-451840 was clinically investigated up to an experimental human malaria infection model, where therapeutic effects could be shown."

1.	Therapeutic Uses